for Second Line+
MONJUVI is an outpatient targeted immunotherapy
for adult patients with NTE DLBCL in 2L1*
The 5-year analysis data from L-MIND have not been submitted to or reviewed by the FDA, and potential inclusion of these data in the final FDA-approved labeling has yet to be determined.
*MONJUVI is a CD19-directed cytolytic monoclonal antibody.1